People · Operator

Percival Barretto-Ko

Named in public records as an officer, director or promoter · active 2025–2025 · Biotechnology

1
Companies
1
Filings
$191.6M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Spruce Biosciences, Inc.BiotechnologySeries C$191.6M$274.5M2025
Operator network

Percival Barretto-Ko at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Michael Grey · 10 companies · 1 sharedMichael GreyTiba Aynechi · 9 companies · 1 sharedTiba AynechiNiall O'Donnell · 7 companies · 1 sharedNiall O'DonnellBali Muralidhar · 3 companies · 1 sharedBali MuralidharRichard King · 3 companies · 1 sharedRichard KingDaniel Spiegelman · 2 companies · 1 sharedDaniel SpiegelmanJONAS HANSSON · 2 companies · 1 sharedJONAS HANSSONCAMILLA SIMPSON · 1 companies · 1 sharedCAMILLA SIMPSONDina Chaya · 1 companies · 1 sharedDina ChayaJavier Szwarcberg · 1 companies · 1 sharedJavier SzwarcbergKirk Ways · 1 companies · 1 sharedKirk WaysRalph William Charlton III · 1 companies · 1 sharedRalph William Cha…Samir Gharib · 1 companies · 1 sharedSamir GharibSimpson Camilla · 1 companies · 1 sharedSimpson CamillaSpruce Biosciences, Inc. · $191.6M raisedSpruce Biosciences, I…Percival Barretto-KoPB
Percival Barretto-Ko Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Percival Barretto-Ko on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Michael Grey110
Tiba Aynechi19
Niall O'Donnell17
Bali Muralidhar13
Richard King13
JONAS HANSSON12
Daniel Spiegelman12
Samir Gharib11
Javier Szwarcberg11
Kirk Ways11
Dina Chaya11
Ralph William Charlton III11
CAMILLA SIMPSON11
Simpson Camilla11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.